Doheny Asset Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Doheny Asset Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,503	Closed	-$367K	–	105
2020 Q3	$367K	Buy	1,503 +793	+112%	+$247K	0.3%	72
2020 Q2	$204K	Buy	+710	New	+$209K	0.19%	82

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Doheny Asset Management's EIGR Position: Q4 2020 in Review

Doheny Asset Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2020, closing a stake of 1,503 shares — an estimated $367K sold.

Doheny Asset Management first reported a position in EIGR in Q2 2020 and held it in 2 quarters. The position peaked at $367K in Q3 2020. 91 funds tracked by Wall St. Rank hold EIGR as of Q4 2020.

Doheny Asset Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Doheny Asset Management sold 1,503 Eiger BioPharmaceuticals, Inc. shares in Q4 2020, an estimated $367K.
Doheny Asset Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2020 and held it in 2 quarters.
Doheny Asset Management's Eiger BioPharmaceuticals, Inc. position peaked at $367K in Q3 2020.
91 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2020.

Based on Doheny Asset Management's 13F filing for Q4 2020, filed 26 Feb 2021.